Endogenous defense mechanism-based neuroprotection in large-vessel acute ischemic stroke: A hope for future
- PMID: 38655439
- PMCID: PMC11034449
- DOI: 10.4103/bc.bc_56_23
Endogenous defense mechanism-based neuroprotection in large-vessel acute ischemic stroke: A hope for future
Abstract
Background: Stroke is a leading cause of morbidity and mortality worldwide and a leading cause of disability. None of the neuroprotective agents have been approved internationally except edaravone in Japanese guidelines in acute ischemic stroke. We here discuss that there are two types of endogenous defense mechanisms (EDMs) after acute stroke for neuromodulation and neuroregeneration, and if both can be activated simultaneously, then we can have better recovery in stroke.
Aims and objectives: We aimed to study the effect of combination of neuroprotection therapies acting on the two wings of EDM in acute large-vessel middle cerebral artery (LMCA) ischemic stroke.
Methods: Sixty patients of LMCA stroke were enrolled and randomized within 72 h into two groups of 30 patients each. The control group received standard medical care without any neuroprotective agents while the intervention group received standard medical care combined with oral citicoline with vinpocetine for 3 months with initial 1 week intravenous and edaravone and cerebrolysin injection, started within 72 h of onset of stroke. Patients were assessed on the basis of the National Institutes of Health Stroke Scale, Fugl-Meyer Assessment Score, Glasgow Coma Scale, and Mini-Mental Status Examination at admission, discharge, and after 90 days.
Results: The intervention group showed significant and early improvements in motor as well as cognitive recovery.
Conclusion: Combination therapy for neuroprotection which is acting on two pathways of EDM can be useful in functional recovery after acute ischemic stroke.
Keywords: Endogenous stroke neuroprotection; multimodal neuroprotection therapy; vinpocetine in stroke.
Copyright: © 2024 Brain Circulation.
Conflict of interest statement
There are no conflicts of interest.
Figures



Similar articles
-
Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.Front Pharmacol. 2024 Nov 7;15:1475021. doi: 10.3389/fphar.2024.1475021. eCollection 2024. Front Pharmacol. 2024. PMID: 39575393 Free PMC article.
-
Efficacy of Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful?J Neurosci Rural Pract. 2019 Oct;10(4):576-581. doi: 10.1055/s-0039-1700790. Epub 2019 Dec 11. J Neurosci Rural Pract. 2019. PMID: 31831974 Free PMC article.
-
Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.Neurocrit Care. 2022 Aug;37(1):314-325. doi: 10.1007/s12028-022-01499-y. Epub 2022 Apr 29. Neurocrit Care. 2022. PMID: 35488169 Free PMC article.
-
Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy.Stroke. 2019 Mar;50(3):652-658. doi: 10.1161/STROKEAHA.118.023815. Stroke. 2019. PMID: 30741623
-
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).Stroke. 2018 Nov;49(11):2568-2576. doi: 10.1161/STROKEAHA.117.020067. Stroke. 2018. PMID: 30355209 Clinical Trial.
Cited by
-
Research progress on remote ischemic conditioning for improving prognosis of patients with acute ischemic stroke.Biochem Biophys Rep. 2025 Jul 30;43:102184. doi: 10.1016/j.bbrep.2025.102184. eCollection 2025 Sep. Biochem Biophys Rep. 2025. PMID: 40791818 Free PMC article. Review.
-
Dragon's Blood Modulates Disulfidptosis-Related Genes to Alleviate Ischemic Brain Injury in Mice.Neurochem Res. 2025 Jun 6;50(3):185. doi: 10.1007/s11064-025-04428-5. Neurochem Res. 2025. PMID: 40478465
-
Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.Front Pharmacol. 2024 Nov 7;15:1475021. doi: 10.3389/fphar.2024.1475021. eCollection 2024. Front Pharmacol. 2024. PMID: 39575393 Free PMC article.
-
Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial.Eur Stroke J. 2025 Feb 14:23969873251319151. doi: 10.1177/23969873251319151. Online ahead of print. Eur Stroke J. 2025. PMID: 39950764 Free PMC article.
-
Time and Tissue Windows in Futile Reperfusion after Ischemic Stroke.Aging Dis. 2024 Oct 21;16(5):2544-2552. doi: 10.14336/AD.2024.1024. Aging Dis. 2024. PMID: 39500359 Free PMC article.
References
-
- Khurana D, Padma MV, Bhatia R, Kaul S, Pandian J, Sylaja PN, et al. Recommendations for the early management of acute ischemic stroke:A consensus statement for healthcare professionals from the Indian Stroke Association. J Stroke Med. 2018;79:113.
-
- Rudberg AS, Berge E, Laska AC, Jutterström S, Näsman P, Sunnerhagen KS, et al. Stroke survivors'priorities for research related to life after stroke. Top Stroke Rehabil. 2021;28:153–8. - PubMed
-
- Sridharan SE, Unnikrishnan JP, Sukumaran S, Sylaja PN, Nayak SD, Sarma PS, et al. Incidence, types, risk factors, and outcome of stroke in a developing country:The Trivandrum Stroke Registry. Stroke. 2009;40:1212–8. - PubMed
LinkOut - more resources
Full Text Sources